US · Healthcare · Biotechnology
EPS came in at -0.18 against a street estimate of -0.22 — a beat of 18.2%.
Analysts rate Climb Bio Inc a strong buy (15 buy, 0 hold, 0 sell out of 15) with an average price target of $27.87.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 19.68% |
| FMR Inc | 11.82% |
| UBS Group AG | 5.93% |
| BRAIDWELL LP | 4.87% |
| Adage Capital Partners Gp LLC | 4.36% |
| BlackRock Inc | 4.10% |
| T. Rowe Price Associates, Inc. | 3.70% |
| Cormorant Asset Management, LLC | 3.67% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Climb Bio announced initial Phase 2 PrisMN data for budoprutug, an anti-CD19 monoclonal antibody, in primary membranous nephropath | 2026-10-26 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • Climb Bio announced additional Phase 1 results for CLYM116/MIL116, an anti-APRIL monoclonal antibody being developed for IgA nephr | 2026-10-23 |
| Reg FD disclosure · Q3 2026 CLIMB BIO, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Climb Bio, Inc. (Nasdaq: CLYM) • Headquarters: Wellesley Hills, Massachusetts • Status: Em | 2026-09-03 |
| Company announcement · Q3 2026 CLIMB BIO, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Climb Bio, Inc. (Nasdaq: CLYM) • Report Date: August 13, 2026 • State of Incorporation: Del | 2026-08-14 |
| Quarterly report · Q2 2026 CLIMB BIO, INC. — 10-Q SUMMARY FOR Q2 2026 HEADLINE NUMBERS • Net Loss (6 months): $27.2 million (vs. $29.4 million in same period 2025) • Net Loss | 2026-08-06 |
| Results announced · Q3 2026 CLIMB BIO Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $239.2 million as of June 30, 2026 • Cash runway extended into second | 2026-08-06 |
| Board / officer change · Q2 2026 CLIMB BIO, INC. - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Climb Bio, Inc. (ticker: CLYM) is a Delaware-incorporated company trading on Nasdaq Gl | 2026-07-01 |
| Quarterly report · Q1 2026 CLIMB BIO, INC. – FORM 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash & Marketable Securities: $146.3 million as of March 31, 2026 (down from $160.6 | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Climb Bio Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.